卡介苗多糖核酸治疗反复呼吸道感染28例临床分析

Clinical Analysis of 28 Cases of Recurrent Respiratory Tract Infections by BCG Polysaccharide Nucleic Acid

目的评价卡介苗多糖核酸治疗反复呼吸道感染疗效。方法方便选取该院2014年7月—2015年8月收治的呼吸道感染患者60例,随机分为观察组28例患者,卡介苗多糖核酸治疗,对照组32例采用常规方法治疗,对比治疗前后呼吸道感染发生情况、免疫指标。结果观察组退出3例,治疗后12个月,观察组[(1.27±0.92)次]与对照组[(4.36±1.85)次]呼吸道感染发生次数低于治疗前12个月[(7.35±3.26)次,(7.67±3.53)次],且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后3个月,组内对比观察组Ig A[(0.84±0.35)g/L]、Ig G[(7.25±2.27)g/L]高于治疗前[(0.52±0.41)g/L、(5.32±2.11)g/L],外周血淋巴细胞计数[(1.14±0.43)×109]、CD4+/CD8+[(1.53±0.31)]水平低于治疗前,治疗后观察组Ig A、Ig G高于对照组[(0.57±0.27)g/L、(5.60±2.14)g/L],外周血淋巴细胞计数、CD4+/CD8+低于对照组[(1.43±0.43)×109、(1.98±0.32)],差异有统计学意义(P<0.05)。结论卡介苗多糖核酸治疗反复呼吸道感染疗效肯定。

Objective This paper tries to evaluate the curative effect of BCG on the treatment of recurrent respiratory infections. Methods 60 patients with respiratory tract infection treated in this hospital from July 2014 to August 2015 were convenient selected and divided into the observation group and the control group, 28 patients in the observation group were treated wtih BCG polysaccharide nucleic acid, 32 cases in the control group were treated by conventional methods, respiratory tract infection, immune index before and after treatment were compared. Results 3 cases were out of the observation group, 12 months after treatment, the respiratory tract infection times in the observation group was（1.27±0.92）times and that of the control group of（4.36±1.85）times, fewer than 12 months before treatment of（7.35±3.26） times,（7.67±3.53）times, and the observation group was fewer than that of the control group, the difference was statistically significant（P〈0.05）. 3 months after treatment, the Ig A and Ig G in the observation group were（0.84±0.35）g/L,（7.25±2.27）g/L, higher than those in the treatment group of（0.52±0.41）g/L,（5.32 ±2.11）g/L, the peripheral blood lymphocyte count was（1.14±0.43）×10^9, CD4＋/CD8＋[（1.53±0.31）], lower than before treatment. After treatment the Ig A and Ig G in the observation group were higher than the control group of（0.57±0.27）g/L and（5.60±2.14）g/L, the peripheral blood lymphocyte counts and CD4＋/CD8＋ were lower than the control group of（1.43±0.43）×10^9,（1.98±0.32）, the difference was statistically significant（P〈0.05）. Conclusion The therapeutic efficacy of BCG is positive for the treatment of recurrent respiratory infections.